SYNBLIA THERAPEUTICS INC has a total of 15 patent applications. Its first patent ever was published in 2018. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are BEIJING LABWORLD BIO MEDICINE TECHNOLOGY CO LTD, PROPELLON THERAPEUTICS INC and FRONTHERA U S PHARMACEUTICALS LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 3 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | Republic of Korea | 2 | |
#6 | United States | 2 | |
#7 | China | 1 | |
#8 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Xie Yinong | 15 |
#2 | Babiss Lee E | 14 |
#3 | Babiss Lee | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021061515A1 | Shp2 inhibitors and uses thereof | |
TW201940167A | SHP2 inhibitors and uses thereof | |
AU2018361229A1 | IRAK4 inhibitors and uses thereof |